Pricing Log in Create free account

Palisade Bio, Inc. (PALI) vs Sol-Gel Technologies Ltd. (SLGL)

Palisade Bio, Inc. and Sol-Gel Technologies Ltd. are both Biotechnology companies. Palisade Bio, Inc. and Sol-Gel Technologies Ltd. are of similar size ($206.3M and $202.2M). Sol-Gel Technologies Ltd. has negative trailing earnings, so its P/E is not meaningful; Palisade Bio, Inc. trades at 1.8×. Palisade Bio, Inc. grew revenue faster over the last twelve months: 5,492.6% against −92.5%. Sol-Gel Technologies Ltd. has the higher net margin (−910.1% vs −4,230.6%) and the lower return on invested capital (−6,630.2% vs 0.00%). Across the 17 metrics below, Sol-Gel Technologies Ltd. leads on 9 and Palisade Bio, Inc. on 8.

Valuation

Metric PALI SLGL Biotechnology median
P/E 1.76 n/m 10.60
P/S 319.17 112.65 9.40
P/B 1.98 4.20 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 154.02 122.35 9.02
Earnings yield 56.81% (9.12%) (32.88%)
Free cash flow yield (7.55%) (10.52%) (23.13%)

Profitability

Metric PALI SLGL Biotechnology median
Gross margin 95.63% 100.00% 68.51%
Operating margin (4,681.99%) (986.96%) 0.00%
Net margin (4,230.60%) (910.14%) 0.00%
Free cash flow margin (2,409.27%) (1,185.18%) 0.00%
Return on equity (51.37%) (40.85%) (51.96%)
Return on assets (47.68%) (35.11%) (46.06%)
Return on invested capital 0.00% (6,630.24%) 0.00%

Growth

Metric PALI SLGL Biotechnology median
Revenue growth (TTM) 5,492.59% (92.50%) 6.76%
EPS growth (last fiscal year) 97.06% 42.37% 29.88%
Revenue growth, 5-year CAGR 72.86% 17.19% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PALI SLGL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 24.26 10.37 4.97
Net debt to EBITDA 7.37 3.23 1.01

Dividend

Metric PALI SLGL Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PALI SLGL Biotechnology median
Market cap 202.16m 206.29m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack